Key Highlights
- First-quarter adjusted EPS reached $0.32, surpassing analyst projections of $0.26–$0.31
- Quarterly revenue totaled $3.91 billion, reflecting a 4.5% year-over-year increase and exceeding the $3.84 billion forecast
- Skin Health and Beauty division drove performance with sales climbing 8.4%
- Kimberly-Clark’s $40 billion acquisition remains scheduled for second half 2026 closure
- Forward-looking projections were withheld as the pending transaction progresses
Kenvue (KVUE) delivered first-quarter financial results on Thursday that surpassed Wall Street projections for both earnings and sales, with shares climbing approximately 1.78% during trading.
The consumer healthcare firm reported adjusted earnings per share of $0.32, exceeding the analyst consensus range of approximately $0.26 to $0.31. Quarterly revenue hit $3.91 billion for the period ending March 29, marking a 4.5% increase from $3.74 billion recorded during the corresponding quarter last year, while surpassing the anticipated $3.84 billion figure.
Organic revenue advanced 0.7%, fueled by 1.0% positive pricing contributions, though partially tempered by a 0.3% decrease in volume.
KVUE experienced a 0.11% decline during pre-market hours before the release, though the strong results helped restore investor confidence.
Chief Executive Kirk Perry highlighted that the organization achieved both net and organic sales expansion for the second quarter running, accompanied by year-over-year gains in gross margin, operating margin, and earnings per share.
Adjusted gross profit margin grew 80 basis points to reach 60.8%, demonstrating supply chain enhancements and positive pricing effects that counterbalanced inflationary pressures and tariff challenges. Adjusted operating income margin climbed to 24.0% compared to 19.8% during the prior-year period.
Skin Health and Beauty Division Powers Growth
The Skin Health and Beauty division emerged as the top performer, recording net sales growth of 8.4% to reach $1.06 billion. Popular brands including Neutrogena and Aveeno generated strong demand across international markets.
Self Care advanced 1.9% while Essential Health posted 4.9% growth. The Self Care segment faced headwinds from a subdued cold and flu season throughout key geographic regions.
The organization indicated that its ongoing restructuring initiative will likely generate pre-tax charges approaching $250 million throughout the current fiscal year.
Kimberly-Clark Acquisition Influences Future Planning
Kenvue declined to provide forward guidance given the pending $40 billion merger with Kimberly-Clark, anticipated to finalize during the second half of 2026, contingent upon international regulatory clearances.
Kimberly-Clark shares advanced roughly 2.05% during the session, with market participants viewing the earnings release positively for the acquiring company.
RBC Capital Markets analyst Nik Modi characterized the results as favorable for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He observed that immediate stock movement will probably depend more heavily on acquisition timing and legal developments rather than core operational performance.
